FNCHQ · Finch Therapeutics Group, Inc. · Debt
$10.35
At close · Sep 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$16.62M
Shares
1.61M
Volume · Sep 23
5800
Avg daily vol (3M)
2195
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current operating lease liabilities | 2024-06-30 | USD 2,094,000 | 10-Q filed 2024-08-13 |
| Noncurrent operating lease liabilities | 2024-06-30 | USD 26,895,000 | 10-Q filed 2024-08-13 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.